Synthesis and In Vitro Cytotoxicity of the 4-(Halogenoanilino)-6-bromoquinazolines and Their 6-(4-Fluorophenyl) Substituted Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase

被引:10
|
作者
Mphahlele, Malose Jack [1 ]
Paumo, Hugues K. [1 ]
Choong, Yee Siew [2 ]
机构
[1] Univ South Africa, Coll Sci Engn & Technol, Dept Chem, Private Bag X06, ZA-1710 Florida, South Africa
[2] Univ Sains Malaysia, Inst Res Mol Med INFORMM, George Town 11800, Malaysia
基金
新加坡国家研究基金会;
关键词
6-bromo-4-chloroquinazolines; amination; Suzuki-Miyaura cross-coupling; cytotoxicity; EGFR-TK; molecular docking; ANTITUMOR-ACTIVITY; BIOLOGICAL EVALUATION; BINDING-SITE; QUINAZOLINE; ANALOGS; FLUORINE; DOMAIN;
D O I
10.3390/ph10040087
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Series of the 2-unsubstituted and 2-(4-chlorophenyl)-substituted 4-anilino-6-bromoquinazolines and their 6-(4-fluorophenyl)-substituted derivatives were evaluated for in vitro cytotoxicity against MCF-7 and HeLa cells. The 2-unsubstituted 4-anilino-6-bromoquinazolines lacked activity, whereas most of their 2-(4-chlorophenyl) substituted derivatives were found to exhibit significant cytotoxicity and selectivity against HeLa cells. Replacement of bromine with 4-fluorophenyl group for the 2-unsubstituted 4-anilinoquinazolines resulted in superior activity against HeLa cells compared to Gefitinib. The presence of a 4-fluorophenyl group in the 2-(4-chlorophenyl) substituted derivatives led to increased cytotoxicity against HeLa cells, except for the 3-chloroanilino derivative. The most active compounds, namely, 3g, 3l, and 4l, were found to exhibit a moderate to significant inhibitory effect against epidermal growth factor receptor tyrosine kinase (EGFR-TK). The EGFR molecular docking model suggested that these compounds are nicely bound to the region of EGFR.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
    Tsou, HR
    Mamuya, N
    Johnson, BD
    Reich, MF
    Gruber, BC
    Ye, F
    Nilakantan, R
    Shen, R
    Discafani, C
    DeBlanc, R
    Davis, R
    Koehn, FE
    Greenberger, LM
    Wang, YF
    Wissner, A
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (17) : 2719 - 2734
  • [22] Tyrosine kinase inhibitors .13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
    Thompson, AM
    Murray, DK
    Elliott, WL
    Fry, DW
    Nelson, JA
    Showalter, HDH
    Roberts, BJ
    Vincent, PW
    Denny, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) : 3915 - 3925
  • [23] Design and synthesis of novel 6-substituted ureido-2-oxindoles derivatives as potent receptor tyrosine kinase inhibitors
    Chern, Ji-Wang
    Khanwelkar, Rahul R.
    Chen, Grace Shiahuy
    Chen, Chien-Shu
    Ko, Ching-Huai
    Lin, Mai-Wei
    Chou, Nien-Tzu
    Liu, Chih-Peng
    Chen, Yen-Chun
    Shih, Ying-Chu
    Hwan, Chrong-Shiong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [24] Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Rao, Guo-Wu
    Xu, Geng-Jie
    Wang, Jian
    Jiang, Xu-Liang
    Li, Hai-Bo
    CHEMMEDCHEM, 2013, 8 (06) : 928 - 933
  • [25] Design, synthesis and anti-inflammatory activity of pyrimidine scaffold benzamide derivatives as epidermal growth factor receptor tyrosine kinase inhibitors
    Thirumurugan, K.
    Lakshmanan, Sivalingam
    Govindaraj, Dharman
    Prabu, D. Sam Daniel
    Ramalakshmi, N.
    Antony, S. Arul
    JOURNAL OF MOLECULAR STRUCTURE, 2018, 1171 : 541 - 550
  • [26] 4-anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase:: syntheses, chemical and pharmacological properties
    Albuschat, R
    Löwe, W
    Weber, M
    Luger, P
    Jendrossek, V
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (12) : 1001 - 1011
  • [27] Tyrosine kinase inhibitors .10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP-binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
    Rewcastle, GW
    Palmer, BD
    Thompson, AM
    Bridges, AJ
    Cody, DR
    Zhou, HR
    Fry, DW
    McMichael, A
    Denny, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (09) : 1823 - 1835
  • [28] Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
    Li, Dong-Dong
    Qin, Ya-Juan
    Sun, Jian
    Li, Jing-Ran
    Fang, Fei
    Du, Qian-Ru
    Qian, Yong
    Gong, Hai-Bin
    Zhu, Hai-Liang
    PLOS ONE, 2013, 8 (08):
  • [29] Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists
    Hasui, Tomoaki
    Ohyabu, Norio
    Ohra, Taiichi
    Fuji, Koji
    Sugimoto, Takahiro
    Fujimoto, Jun
    Asano, Kouhei
    Oosawa, Masato
    Shiotani, Sachiko
    Nishigaki, Nobuhiro
    Kusumoto, Keiji
    Matsui, Hideki
    Mizukami, Atsushi
    Habuka, Noriyuki
    Sogabe, Satoshi
    Endo, Satoshi
    Ono, Midori
    Siedem, Christopher S.
    Tang, Tony P.
    Gauthier, Cassandra
    De Meese, Lisa A.
    Boyd, Steven A.
    Fukumoto, Shoji
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (19) : 5428 - 5445
  • [30] Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors
    Jin, Cheng Hua
    Krishnaiah, Maddeboina
    Sreenu, Domalapally
    Rao, Kota Sudhakar
    Subrahmanyam, Vura Bala
    Park, Chul-Yong
    Son, Jee-Yeon
    Sheen, Yhun Yhong
    Kim, Dae-Kee
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (08) : 2633 - 2640